Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Clinical Development Programs for Opioid Conversion; Public Workshop; Request for Comments

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) is announcing a scientific workshop to address public health concerns associated with the inclusion of equianalgesic opioid  conversion tables in opioid product labels.  Discussion will focus on the available data supporting the use of equianalgesic opioid conversion tables, problems associated with their use, strategies used in clinical practice to convert patients from one opioid analgesic product to another, gaps in existing knowledge regarding equianalgesic opioid conversion in clinical practice, a research agenda to address these gaps, and identification of mechanisms for communicating opioid analgesic conversion strategies to prescribers.


July 29, 2013


8:00 a.m. to 4:30


FDA White Oak Campus
10903 New Hampshire Avenue,
Bldg. 31, Room 1503 (Great Room)
Silver Spring, Maryland 20993

Registration to Attend the Workshop and Requests to Participate in Open Public Hearing

If you wish to attend the meeting or provide testimony  for the open public hearing , please email your registration by July 15, 2013. Those without email access may register by contacting one of the persons listed in the Contacts section of the document. Please provide complete contact information for each attendee, including name, title, affiliation, address, email address, and telephone number.



Page Last Updated: 04/19/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English